APEPTICO - Innovation in peptide drugs
Meet APEPTICO
At the BIO-Europe (October 31st - November 2nd, 2011): APEPTICO Forschung und Entwicklung GmbH participates at the Bio-Europe in Duesseldorf, Germany. BIO-Europe is Europe's largest partnering conference, serving the global biotechnology industry.
At the 2011 ERS Annual Congress (September 24th-28nd, 2011): During the 2011 Annual Congres of the European Respiratory Socienty in Amsterdam, Apeptico Forschung und Entwicklung GmbH will present significant research results of its inhalation therapy for prevention and treatment of Oedematous Respiratory Failure to the scientific community.
At the Bio International Convention (June 27th - 30th, 2011): Apeptico Forschung und Entwicklung GmbH will attend the BIO International Convention (Washington DC). We will exhibit at booth 3137 (Austria Pavilion) and present latest finding of the AP301 clinical study during the Company Presentation event.
At the BIO-Europe (November 15th-17th, 2010): APEPTICO Forschung und Entwicklung GmbH takes part at the Bio-Europe in Munich, Germany. BIO-Europe is Europe's largest partnering conference, serving the global biotechnology industry.
At the 20th ERS Annual Congress (September 18th-22nd, 2010): During the 20th Annual Congres of the European Respiratory Socienty in Barcelona, Apeptico Forschung und Entwicklung GmbH will present its most recent study results of AP301 lead peptide in the tracheal inhalaltion model of Acute Lung Injury / Acute Respiratory Distress Syndrom.
At the BIO (May 2nd-5th, 2010): Apeptico Forschung und Entwicklung GmbH will attend the BIO International Convention (Chicago).
At the BioSquare (February 1st-2nd, 2010) and Bio-Europe Spring (March 8th-10th, 2010): Apeptico Forschung und Entwicklung GmbH will present the company and development products at the BioSquare (Geneva) and Bio-Europe Spring (Barcelona).
At the Bio-Europe (November 2nd-4th, 2009): APEPTICO Forschung und Entwicklung GmbH takes part at the Bio-Europe in Vienna, Austria. BIO-Europe is Europe's largest partnering conference, serving the global biotechnology industry.
At the Science4Life Messe (October 22nd, 2009): APEPTICO Forschung und Entwicklung GmbH will present its development compounds at the Science4Life Messe in Frankfurt, Germany.
At the CPhI (October 13th-15th, 2009): APEPTICO Forschung und Entwicklung GmbH will attend this year's CPhI in Madrid, Spain. The event covers more than 50,000 sq m of exhibition space, hosting over 1,400 exhibitors and is the market leader for the global pharmaceuticals ingredients industry.
News
The patent “Prevention and Treatment of Hyperpermeability” invented and owned by APEPTICO ranks among the 10 most innovative inventions of the year 2011 in Austria.
Vienna, Austria, 26th January, 2012- The patent “Prevention and Treatment of Hyperpermeability” invented and owned by APEPTICO ranks among the 10 most innovative inventions of the year 2011 in Austria. Today, APEPTICO’s patent AT 507 953 was awarded the INVENTUM nomination based on a decision of a jury composed of patent experts of the Austrian Patent Office and the Federal Ministry for Transport, Innovation and Technology.
APEPTICO Announces Successful Completion of Phase I Trial with AP301 in Oedematous Respiratory Failure
Vienna, Austria, 25th October, 2011- APEPTICO GmbH, a biotechnology company developing peptide drugs based on its PEPBASE™ discovery technology, today announced completion of a Phase I clinical trial for its pulmonary sodium ion channel activator AP301. The orally inhaled drug candidate was safe and well-tolerated by all study participants. AP301 is being developed for the prevention and treatment of oedematous respiratory failure in patients suffering from lung infection, lung injury and lung transplantation.
The Annual Congress of the European Respiratory Society (Amsterdam, 2011) has been a major success for APEPTICO's development compound AP301
29th September, 2011, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs for the treatment of life threatening lung diseases today announced that the 2011 Annual Conference of the European Respiratory Society has been a major success for the company.
APEPTICO presents significant research results of its inhalation therapy for prevention and treatment of Oedematous Respiratory Failure at the 2011 Annual Congress of the European Respiratory Society
09th September, 2011, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs for the treatment of life threatening lung diseases today announced that it will present significant research results of its inhalation therapy for prevention and treatment of Oedematous Respiratory Failure at the 2011 Annual Congress of the European Respiratory Society.
APEPTICO initiates a Phase I clinical trial with its lead product AP301
Vienna, Austria, April 07, 2011 - APEPTICO, a privately-held biotechnology company developing peptide drugs based on its PEPBASE™ discovery technology, today announced the initiation of a Phase I clinical trial with its lead product AP301 to assess the safety and tolerability of the orally inhaled peptide drug. AP301 is being developed for the treatment of oedematous respiratory failure in patients suffering from lung infection, lung injury and lung transplantation.
The 2010 Annual Conference of the European Respiratory Socoety has been a major success for APEPTICO
The beneficial pharmacodynamic effects APEPTICO’s development compound AP301, also known as “TIP Peptide”, have been subject of three presentations.
APEPTICO's lead molecule AP301 has been validated in the porcine model of lung injury by inhalation of the peptide-aerosol
01th July, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH today announced that it has validated its lead molecule AP301 in the porcine model of lung injury by inhalation of the peptide-aerosol. In a poricine model of acute lung injury, APEPTICO's TIP-peptide AP301 was appplied vs. a control nebulisation of WFI under comparable ventilator settings and hemodynamic conditions. A sustained improvement of the lung function was recorded following AP301 nebulisation according to the parameters oxygenation index, extravascular lung water and pulmonary shunt fraction.
APEPTICO GmbH closes second financing round
05th August, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced completion of a €3 million financing round. This equity financing combined existing and new investors from Germany and Switzerland. As an integral part of the financing round, APEPTICO will receive a €1.2 million research grant from the Austrian Research Promotion Agency (FFG).
APEPTICO's lead molecule AP301 has been validated in the experimental lung transplantation model to prevent ischemia reperfusion injury
23rd February, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that it's lead molecule AP301 has been validated in the experimental lung transplantation model where intratracheal application of AP301 dramatically improved oxygenation after lung transplantation.
APEPTICO granted Orphan Drug Designation by FDA for development compound AP301
10th February, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that it has received Orphan Drug Designation in the USA from the Food and Drug Administration (FDA) for APEPTICO's development compound AP301. AP301 has been granted Orphan Drug Designation in the USA for "prevention of ischemia reperfusion injury in the lung during lung transplantation".
APEPTICO presents its lead product AP301 at the Annual Congress of the European Respiratory Society in Vienna, Austria
08th September, 2009, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing a novel peptide-based drug for the treatment of the life threatening disease “Acute Lung Injury” today announced, that it will present its most recent scientific results for APEPTICO’s lead compound AP301 at the Annual Congress of the European Respiratory Society which starts on 12th September 2009 in Vienna, Austria.
APEPTICO granted Orphan Medicinal Product Designation by EMEA for lead product AP301
20th July, 2009, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that it has received Orphan Medicinal Product Designation in the European Union from the European Medicines Agency (EMEA) for APEPTICO’s lead product AP301 (“Human tumour necrosis factor alpha-derived peptide”) for the “treatment of Acute Lung Injury”.
APEPTICO GmbH erhält Preis anlässlich der Verleihung des “Venture Capital & Private Equity Award Österreichs“
09. Juni 2009, Wien, Österreich: APEPTICO Forschung und Entwicklung GmbH teilt mit, dass das Unternehmen anlässlich der Verleihung des “Venture Capital & Private Equity Award Österreichs“ mit einem Preis ausgezeichnet wurde. Dieser Preis wurde durch den „Styria Börse Express“ und die „Junge Industrie“ verliehen und stellt eine Anerkennung für die kürzlich abgeschlossene Finanzierung des Unternehmens durch Investoren und Österreichische Fördergeber dar.
APEPTICO GmbH closes seed financing round
29th May, 2009, Vienna, Austria: APEPTICO, a biotechnology company developing novel peptide-based drugs, announced completion of a seed financing round. The EUR 1Mio equity financing round was led by The BioScience Ventures Group AG (BSVG, www.bsvg.com, Munich/Germany) and included the participation of the Swiss business angel Dr. Jürg Geigy. Both, BSVG and Dr. Geigy are specialised in early stage investments in the biotech industry. The completion of the financing round entitled APEPTICO to receive a grant of EUR 1.2 Mio from the Austrian Research Promotion Agency (FFG).
Medical breakthrough for treatment of Acute Lung Injury
26th March, 2009, Vienna, Austria: Based on intensive research and comprehensive in-vitro and in-vivo studies APEPTICO Forschung und Entwicklung GmbH, a Vienna development stage biotechnology company, has clarified the mode of action of its development compound AP301. Up to date there exists no approved drug molecule for the treatment of Acute Lung Injury. Up to 100,000 patients in Europe could benefit from the new discovery.